Intuitive Surgical Faces Competition Despite Strong Surgeon Adoption

ISRG shares have lagged peers even as surgeon demand for its Da Vinci 5 platform keeps climbing. The relative underperformance was also flagged separately in market coverage this week, a divergence that sits against the company's own numbers: Q2 2026 revenue rose 19% to $2.89 billion, with da Vinci 5 placements up 37% year-over-year to 246 units and the installed base growing 12% to 11,710 systems.

Analyst views diverge sharply. One Wall Street analyst has modeled a bull-case return as high as 85% for the shares, a forecast that stands out against an otherwise lukewarm market reaction. That dispersion, more than any single target, is the useful signal: it reflects genuine disagreement over how much of Intuitive's roughly 80% share of the soft-tissue robotic surgery market stays defensible as rivals scale up.

That competition is no longer hypothetical. Medtronic's Hugo won US approval in late 2025, and JNJ's Ottava robot cleared FDA authorization in mid-2026, pitching a table-integrated "new category" rather than a da Vinci clone; Stryker's Mako and CMR Surgical's Versius add adjacent pressure. None has blanket approval yet, so the threat stays confined to specific procedures for now, but the field has gone from one dominant player to several credible ones within a year.

Related Stocks

• ISRG